87 patents currently held
27 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
25 more records may belong here and await a decision; they are not counted.
The next term ends in May 2028. from the record
Of the 27 now held by other companies, 18 were conveyed to H Lundbeck a S in the filing they arrived in, and 9 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
May 2028
Next term end
52
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2031 · High confidence
Also notable
Ends Sep 2029 · High confidence
Also notable
Ends Apr 2038 · High confidence
Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
US 9,150,663
The most cited patent in this portfolio, cited by 164 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2031.
Combination Treatment of CD38-Expressing Tumors
US 9,040,050
Cited by 112 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof
US 11,512,137
Cited by 12 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2038.
Formerly held, still cited
Notable
Ends Jul 2036 · High confidence
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
conveyed to H. Lundbeck A/S
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 30, 2026 · next Dec 18
- 3 fees due Jan 9 to 21, 2027 · next Jan 9
- 1 fee due Mar 10, 2027The maintenance fee for Humanized or Chimeric CD3 Antibodies (US 10,407,501) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 4 fees due Apr 6 to 27, 2027 · next Apr 6
- 2 fees due May 5 to 14, 2027 · next May 5
- 4 fees due Jun 10 to 24, 2027 · next Jun 10
- 3 fees due Jul 2 to 28, 2027 · next Jul 2
- 1 fee due Aug 2, 2027The maintenance fee for Antibodies Against Human CD38 (US 9,249,226) comes due Aug 2, 2027. Unpaid by Feb 2, 2028, it lapses early.
- 3 fees due Sep 17 to 24, 2027 · next Sep 17
- 3 fees due Oct 14 to 30, 2027 · next Oct 14
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
- 2 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 52 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof | 5 in force | to Jan 2039 |
| Antibodies Binding Axl | 5 in force | to Jul 2035 |
| Binding Agents Binding to PD-L1 and CD137 and Use Thereof | 4 in force | to Oct 2041 |
| Antibodies | 3 in force | to Jul 2040 |
| Humanized or Chimeric CD3 Antibodies | 3 in force | to Mar 2039 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,351,629 | Recombinant IGG4 Monovalent Antibodies In force · High confidence | In force | High confidence | |
| US 9,663,578 | Monoclonal Antibodies Against CD32B In force · High confidence | In force | High confidence | |
| US 10,155,816 | Recombinant Monovalent Antibodies and Methods for Production Thereof In force · High confidence | In force | High confidence | |
| US 10,906,991 | Bispecific Antibodies and Methods for Production Thereof In force · High confidence | In force | High confidence | |
| US 10,752,695 | STABLE IgG4 ANTIBODIES In force · High confidence | In force | High confidence | |
| US 9,580,506 | Potency assays for antibody drug substance binding to an fc receptor In force · High confidence | In force | High confidence | |
| US 9,040,050 | Combination Treatment of CD38-Expressing Tumors In force · High confidence | In force | High confidence | |
| US 10,000,570 | Antibody Variants Having Modifications in the Constant Region In force · High confidence | In force | High confidence | |
| US 9,492,565 | Human Antibody Drug Conjugates Against Tissue Factor In force · High confidence | In force | High confidence | |
| US 9,714,297 | Human Antibodies Against Tissue Factor and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 87: 27 patents in force now held by others · 25 patents ended · 95 applications pending · 95 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.